JPMorgan lowered the firm’s price target on BioAtla to $14 from $17 and keeps an Overweight rating on the shares. The analyst updated models in the small cap biotechnology space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BCAB:
